FDA Decision July 24 on New ADHD Drug: What the Numbers Show
Last updated:
If stimulant ADHD medications haven’t worked for your child, or have made an existing anxiety worse, you’ve been choosing from a short list for a long time. The non-stimulant options that exist — atomoxetine, guanfacine, clonidine — are useful for some and insufficient for others. None of them address attention and anxiety together.
July 24 is a date worth tracking. That is when the FDA is expected to make its decision on centanafadine, a new non-stimulant ADHD medication for children, adolescents, and adults. Three Phase 3 randomized controlled trials back the application with solid verified data. For families caught between ADHD and anxiety with no good single option, the results are genuinely meaningful.
The trial numbers are real. But “statistically significant improvement on the AISRS rating scale” is a different question from “will my child build executive function skills and do better in school this fall.” Parents looking at July 24 deserve both answers.
TL;DR
Centanafadine (Otsuka) is a non-stimulant ADHD drug under FDA Priority Review covering children ages 6+, adolescents, and adults; PDUFA decision date is July 24, 2026.
Phase 3 RCTs showed statistically significant ADHD symptom improvement across all ages: in children, 34% reached clinically meaningful reduction versus 23% on placebo; adults with comorbid anxiety showed AISRS improvement of 18.5 vs 12.6 points (p < 0.0001).
The drug also improved anxiety symptoms in adults with ADHD and comorbid anxiety disorder (HAM-A −12.5 vs −10.6), a clinically relevant finding for the roughly 50% of children with ADHD who have co-occurring anxiety.
Stimulant ADHD medications frequently worsen anxiety; centanafadine’s triple reuptake mechanism (norepinephrine, dopamine, serotonin) differs from all existing non-stimulant ADHD options.
The NIMH MTA study (N=579) found medication alone did not produce academic or social-skills gains; combined treatment did — a finding that applies to any ADHD medication, stimulant or not.
The FDA is expected to rule on centanafadine — the first new-mechanism non-stimulant ADHD drug in decades — on July 24. Here is what the Phase 3 data shows across children, adolescents, and adults, and the one question the press releases don’t answer.
Common questions
How is centanafadine different from Strattera (atomoxetine)?
Both are non-stimulants, but the mechanisms differ. Strattera targets only norepinephrine reuptake. Centanafadine is a triple reuptake inhibitor: norepinephrine, dopamine, and serotonin. The serotonin component is what researchers believe accounts for the anxiety reduction seen in the Phase 3b trial, making it a different clinical profile from any existing non-stimulant ADHD option. Guanfacine and clonidine work on a different receptor entirely and address hyperactivity and impulsivity more than inattention.
My child has ADHD and anxiety. Do stimulants always make anxiety worse?
Not always, but it is a well-documented and common pattern. Stimulants raise dopamine and norepinephrine, which increases arousal and improves attention. In a child already prone to anxiety, that same arousal increase frequently worsens anxiety symptoms. Some children tolerate stimulants without anxiety effects; others do not. If your child has both ADHD and anxiety and has struggled with stimulants, centanafadine’s mechanism and trial data are worth discussing with the prescriber after July 24.
Will ADHD medication improve my child’s reading or school performance?
Medication reduces ADHD symptoms and improves the conditions for learning, which is real and valuable. But the NIMH MTA study — the largest ADHD intervention trial ever conducted, 579 children over 14 months — found that medication alone did not produce significant gains in academic performance or social skills. Only combined treatment (medication plus structured behavioral and skill-building support) produced those broader outcomes. Medication changes the environment for learning. The skill-building still requires intentional, separate work.
How do I know if my child has ADHD-type attention challenges before getting a formal evaluation?
A screener is a starting point. It tells you where your child is today, in language that identifies specific patterns without boxing them in with a label. A screener is not a diagnosis and is not meant to replace a professional evaluation — if your child might need formal school supports like an IEP or 504 plan, or you suspect a vision, hearing, or medical cause, a professional evaluation is the only route to those supports. But a screener gives you organized, specific observations before you walk into an evaluation room, and that specificity is what helps a clinician see what you see at home.
Otsuka Pharmaceutical submitted a New Drug Application to the FDA for centanafadine in late 2025. The FDA accepted it for Priority Review, signaling it addresses an unmet medical need, with a Prescription Drug User Fee Act target decision date of July 24, 2026. The application covers children ages 6 and up, adolescents, and adults.
Three clinical trials supported the filing. A Phase 3 trial in 480 children ages 6 to 12 found high-dose centanafadine significantly outperformed placebo on the ADHD Rating Scale-5: 34% of children in the high-dose group achieved a clinically meaningful reduction (18 or more points) versus 23% in the placebo group. A separate Phase 3 trial in 459 adolescents ages 13 to 17 confirmed high-dose superiority over placebo and over the lower dose. Both trials ran six weeks. The most common side effects across age groups were decreased appetite, nausea, and fatigue, described as generally mild.
A Phase 3b trial in 315 adults with ADHD and comorbid anxiety disorder showed statistically significant improvement on the Adult Investigator Symptom Rating Scale (AISRS): centanafadine achieved a mean reduction of 18.5 points versus 12.6 for placebo (p < 0.0001). Anxiety symptoms also improved: centanafadine produced a Hamilton Anxiety Rating Scale reduction of 12.5 points versus 10.6 for placebo.
Centanafadine works differently from existing non-stimulants. It is a norepinephrine, dopamine, and serotonin reuptake inhibitor — a triple reuptake inhibitor — the first in that class proposed for ADHD. Atomoxetine (Strattera) targets only norepinephrine. Guanfacine and clonidine target a different receptor entirely. The addition of serotonin reuptake inhibition is what researchers believe accounts for the anxiety benefit seen in the Phase 3b trial.
What the coverage gets wrong
Most reporting on new ADHD medications frames FDA approval as a treatment solution: new drug approved, families have better options, progress made. That framing leaves out what the NIMH Multimodal Treatment Study of ADHD established across 579 children: medication alone improved ADHD symptoms but did not produce meaningful gains in academic performance, social skills, or parent-child relations. Combined treatment — medication plus structured behavioral and skill-building support — did. Centanafadine is a genuine advance for families where stimulants have failed or worsened anxiety. Treating it as the complete answer misses what decades of ADHD outcome research actually shows about where medication’s work ends and skill-building’s work begins.
Why the anxiety finding changes the picture for many families
Approximately half of children with ADHD have a co-occurring anxiety disorder. For those families, stimulant medications create a real dilemma. Amphetamines and methylphenidate increase dopamine and norepinephrine and raise arousal — which improves attention but frequently worsens anxiety in a child who is already anxious. The result is a parent forced to choose between two problems with no tool that addresses both. Centanafadine’s trial data suggests it addresses both simultaneously. That is a clinically meaningful difference for a predictable group of children who have been stuck in that either/or.
But the mainstream coverage of a new ADHD medication approval — “new drug, better treatment options” — routinely skips what the research on ADHD outcomes actually shows about what medication does and does not do. The NIMH Multimodal Treatment Study of ADHD, the largest ADHD intervention trial ever conducted (579 children, ages 7 to 9, 14 months of treatment), found that both medication-alone and combined treatment significantly reduced ADHD symptoms. But combined treatment — medication paired with intensive behavioral support — was the only group to show meaningful improvements in academic performance, parent-child relations, and social skills. Medication alone produced equivalent ADHD symptom scores without those broader gains. By the 36-month follow-up, the advantage of the medication group had largely faded; what remained was the benefit of skill-building.
Centanafadine is a non-stimulant. But the MTA finding holds for ADHD medication generally: a pill changes the symptom environment. It does not build executive function skills, it does not develop working memory or processing speed, and it does not do the work of teaching a child to manage their own attention. The framing that a prescription fills the gap leaves that part out. A new medication option is valuable. Treating it as the answer is where families get stuck.
Key Takeaways:
1
FDA decides July 24: Centanafadine, a first-in-class non-stimulant ADHD drug for children, adolescents, and adults, reaches its FDA decision date this month after Phase 3 trials in all age groups confirmed statistically significant symptom improvement.
2
The anxiety comorbidity changes the calculation: About half of children with ADHD have co-occurring anxiety; stimulants frequently worsen anxiety in that population, and centanafadine’s Phase 3b trial showed it improved both ADHD symptoms and anxiety scores simultaneously.
3
Medication and skill-building are separate jobs: The landmark NIMH MTA study (579 children) found medication alone did not improve academic performance or social skills; only combined treatment (medication plus behavioral support) produced those broader gains alongside symptom reduction.
What this means for your child this month
If July 24 passes and the FDA approves centanafadine, it will be good news for two specific groups: families who have tried stimulants and found them ineffective or intolerable, and families whose child has ADHD alongside anxiety and has been caught in the stimulant-worsens-anxiety bind. For those families, a new mechanism with clean Phase 3 data across ages is a real expansion of options worth discussing with a prescriber.
The questions worth asking go beyond what the clinical summary sheet covers. Beyond symptom scores on a rating scale, what does improvement look like in terms the school would see? Is a skill-building plan in place alongside any medication? Who is tracking executive function development, working memory, and reading fluency — not only behavior ratings from teachers? A child whose attention scores improve on a trial instrument while the underlying cognitive skills go unaddressed will still hit a ceiling. The medication changes the conditions; the building still has to happen.
If you suspect your child has ADHD-type attention challenges and you’re watching for what a potential new treatment option means, a screener is a useful starting point. A screener tells you where your child is today, in language that builds them up. It is not a diagnosis, and it is not a substitute for one — if your child might need formal school supports like an IEP or 504 plan, or you suspect a vision, hearing, or medical cause, a professional evaluation is the route to those supports. But the screener gives you organized, specific information before you walk into that evaluation room, and specific information is what gets children the right support faster.
The problem centanafadine solves is real: a child whose attention struggles are entangled with anxiety, for whom every stimulant option makes the second problem worse. For that child and that family, a new mechanism with solid Phase 3 data is a meaningful new door. The obstacle is not the medication itself — it is the assumption that the prescription is where the treatment ends. Your child’s brain learns differently. Understanding which systems need support, and building those skills alongside whatever medical support is in place, is what turns a better symptom score into a child who actually reads better and feels capable. The Learning Success Brain Bloom System is built around exactly that work: the cognitive micro-skills — working memory, auditory and visual processing, executive function — that medication alone does not build. Try All Access today.
Is Your Child Struggling in School?
Get Your FREE Personalized Learning Roadmap
Comprehensive assessment + instant access to research-backed strategies
